Product overview

  • Name
    Rapamycin
  • Short description
    mTOR inhibitor and potent immunosuppressant
  • Biological description

    mTOR inhibitor and potent immunosuppressant.

    Complexes with FKBP12 to bind mTORC1 to inhibit mTOR activity and block subsequent activation of p70 s6 kinase (IC50 = 50 pM).

    Induces autophagy and apoptosis.

    Promotes hPSC differentiation to blood progenitor and mesendoderm cells.

    Rapamycin can also be used in inducible CRISPR/Cas9 systems to enable inducible gene editing.

    Active in vivo.

  • Alternative names
    Sirolimus
  • Biological action
    Antibiotic
  • Mode of action
    interferes with protien synthesis by enzyme inhibition
  • Antibiotic Spectrum
    yeast and fungi
  • Purity
    >98%
  • Our products in action

Properties

  • Chemical name
    (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
  • Molecular Weight
    914.18
  • Molecular Formula
    C51H79NO13
  • CAS Number
    53123-88-9
  • PubChem identifier
    5284616
  • SMILES
    C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
  • InChiKey
    QFJCIRLUMZQUOT-HPLJOQBZSA-N
  • MDL number
    MFCD00867594
  • Appearance
    White to off-white

Storing and Using Your Product

  • Storage instructions
    -20 °C;
  • Solubility overview
    Soluble in ethanol (20 mM) and DMSO (50 mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for Rapamycin

  • Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.

    Kobayashi et al (2007) Cancer Sci 98(5) : 726-33
    PubMedID: 17425689
  • Rapamycins: mechanism of action and cellular resistance.

    Huang et al (2003) Cancer Biol Ther 2(3) : 222-32
    PubMedID: 12878853
  • Chemical modulators of autophagy as biological probes and potential therapeutics.

    Flemin et al (2011) Nat Chem Biol 7(1) : 9-17
    PubMedID: 21164513
  • A split-Cas9 architecture for inducible genome editing and transcription modulation.

    Zetsche et al (2015) Nat Biotechnol 33(2) : 139-42
    PubMedID: 25643054